Michael Castro, MD
Internal Medicine · Glendale, AZNPI 1639170293
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 585 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,659 and has fallen 82.4% since, to $643 in 2025. Among internal medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 585 payments — averaging $27.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$2K
- Novo Nordisk$2K
- AbbVie$1K
- Pfizer$697
- Boston Scientific$691
- plus $7K from 54 others
Across 23 payments — averaging $6086.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$75K
- Ironwood Pharmaceuticals, Inc$65K
What the payments were for
- Consulting fees$3002%
- Food & beverage$15,15193%
- Education$8095%
- Entertainment$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$1,143
- Ozempic$517
- FARXIGA$454
- Indigo System$297
- BRILINTA$229
- LifeVest$214
- Abre$168
- BioMonitor$148
- MitraClip$145
- Orserdu$142
- SAPIEN 3 Ultra RESILIA$140
- GENERAL BRADY$136
- Impella$134
- Edwards SAPIEN 3 Transcatheter Heart Valve$131
- Tavneos$125
- WAINUA$125
- KRYSTEXXA$125
- Korlym$125
- Inpefa$125
- TERLIVAZ$122
How this compares
$16,279 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $139,428 |
| MounjaroTirzepatide | 67 | $92,089 |
| JardianceEmpagliflozin | 60 | $88,605 |
| FarxigaDapagliflozin Propanediol | 78 | $86,620 |
| EliquisApixaban | 52 | $58,439 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 33 | $26,963 |
| VascepaIcosapent Ethyl | 51 | $26,556 |
| TrulicityDulaglutide | 14 | $22,486 |
| LinzessLinaclotide | 30 | $20,378 |
| XareltoRivaroxaban | 11 | $16,926 |
| MyrbetriqMirabegron | 13 | $16,494 |
| EntrestoSacubitril/Valsartan | 13 | $15,733 |
| SynthroidLevothyroxine Sodium | 111 | $9,771 |
| EdarbiAzilsartan Medoxomil | 21 | $9,727 |
| Rosuvastatin Calcium | 357 | $4,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,727 | $139,428106 claims |
| Lilly USA, LLCMounjaro, Trulicity | $146 | $114,57481 claims |
| Boehringer IngelheimJardiance | $256 | $88,60560 claims |
| AstraZenecaFarxiga | $2,315 | $86,62078 claims |
| PfizerEliquis | $697 | $58,43952 claims |
| AbbVieLinzess, Synthroid | $1,210 | $30,149141 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $297 | $26,96333 claims |
| Johnson & JohnsonXarelto | $125 | $16,92611 claims |
| Astellas Pharma US IncMyrbetriq | $115 | $16,49413 claims |
| NovartisEntresto | $260 | $15,73313 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $156 | $9,72721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Glendale
- Christine HarterGlendale$127K
- George AvilesGlendale$18K
- Bindu RajanGlendale$16K
- Frank LovecchioPhoenix$911K
- Nasser HajaigPhoenix$687K
- Rajesh JanardhananTucson$685K
- Mona SelejTucson$440K
- Kelly KrohnPhoenix$262K
- Jacque SokolovScottsdale$235K
- Paul StanderPhoenix$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.